Validation Value of the Questionnaire to Assess Health-related Quality of Life in Patients With CML
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- CML (Chronic Myelogenous Leukemia)
- Sponsor
- xuna
- Enrollment
- 10000
- Locations
- 1
- Primary Endpoint
- Assess health-related Quality of Life and Symptom Burden in patients with chronic myeloid leukemia
- Last Updated
- 4 years ago
Overview
Brief Summary
Successful outcomes in CML require both prolonged adherence to oral TKI therapy by patients and careful monitoring of treatment responses by their physicians. Patient Reported Outcomes(PRO) assessment is important to facilitate decisions in the current treatment landscape of CML.
Detailed Description
1. Above 18 years of age. 2. Patient with confirmed diagnosis of Philadelphia chromosome positive and/or BCR-ABL positive chronic myeloid leukemia (CML). 3. Written informed consent. 4. Patients enrolled in investigational drug-trials or other type of clinical trials are also eligible.
Investigators
xuna
professor
Nanfang Hospital, Southern Medical University
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Assess health-related Quality of Life and Symptom Burden in patients with chronic myeloid leukemia
Time Frame: 1 year
Health-related quality of life (HRQOL) assessment in the current treatment landscape of chronic myeloid leukemia